These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 7844602)

  • 41. Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer.
    Malone CC; Schiltz PM; Mackintosh AD; Beutel LD; Heinemann FS; Dillman RO
    Cancer Biother Radiopharm; 2001 Oct; 16(5):381-90. PubMed ID: 11776755
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.
    Topalian SL; Solomon D; Avis FP; Chang AE; Freerksen DL; Linehan WM; Lotze MT; Robertson CN; Seipp CA; Simon P
    J Clin Oncol; 1988 May; 6(5):839-53. PubMed ID: 3259261
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma.
    Fisher B; Packard BS; Read EJ; Carrasquillo JA; Carter CS; Topalian SL; Yang JC; Yolles P; Larson SM; Rosenberg SA
    J Clin Oncol; 1989 Feb; 7(2):250-61. PubMed ID: 2644399
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience.
    Yannelli JR; Hyatt C; McConnell S; Hines K; Jacknin L; Parker L; Sanders M; Rosenberg SA
    Int J Cancer; 1996 Feb; 65(4):413-21. PubMed ID: 8621219
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma.
    Markel G; Cohen-Sinai T; Besser MJ; Oved K; Itzhaki O; Seidman R; Fridman E; Treves AJ; Keisari Y; Dotan Z; Ramon J; Schachter J
    Anticancer Res; 2009 Jan; 29(1):145-54. PubMed ID: 19331144
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetically marking human cells--results of the first clinical gene transfer studies.
    Cai Q; Rubin JT; Lotze MT
    Cancer Gene Ther; 1995 Jun; 2(2):125-36. PubMed ID: 7621260
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intratumoral adoptive immunotherapy with tumor infiltrating lymphocytes (TIL) in a melanoma patient leading to regression of local tumor mass. A case report.
    Möller P; Wittig B; Schadendorf D
    Anticancer Res; 1998; 18(2B):1237-41. PubMed ID: 9615794
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor localization by tumor infiltrating lymphocytes labeled with indium-111 in patients with metastatic renal cell carcinoma, melanoma, and colorectal cancer.
    Dillman RO; Hurwitz SR; Schiltz PM; Barth NM; Beutel LD; Nayak SK; O'Connor AA
    Cancer Biother Radiopharm; 1997 Apr; 12(2):65-71. PubMed ID: 10851449
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
    Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
    Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience.
    Galanis E; Hersh EM; Stopeck AT; Gonzalez R; Burch P; Spier C; Akporiaye ET; Rinehart JJ; Edmonson J; Sobol RE; Forscher C; Sondak VK; Lewis BD; Unger EC; O'Driscoll M; Selk L; Rubin J
    J Clin Oncol; 1999 Oct; 17(10):3313-23. PubMed ID: 10506635
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
    Tian JQ; Wang ZP; Rodriguez R; Fu JS; Lu JZ; Ma BL
    Urology; 2006 May; 67(5):1093-8. PubMed ID: 16635513
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.
    Schwartzentruber DJ; Hom SS; Dadmarz R; White DE; Yannelli JR; Steinberg SM; Rosenberg SA; Topalian SL
    J Clin Oncol; 1994 Jul; 12(7):1475-83. PubMed ID: 8021739
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials.
    Hwu P; Rosenberg SA
    Cancer Detect Prev; 1994; 18(1):43-50. PubMed ID: 8162605
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cancer immunotherapy using tumor-infiltrating lymphocytes.
    Figlin RA
    Semin Hematol; 1992 Apr; 29(2 Suppl 1):33-5. PubMed ID: 1535456
    [No Abstract]   [Full Text] [Related]  

  • 55. NeoR-based transduced T lymphocytes detected by real-time quantitative polymerase chain reaction.
    Venditti G; Di Ianni M; Falzetti F; Moretti L; Di Florio S; Tabilio A
    J Hematother Stem Cell Res; 2003 Feb; 12(1):83-91. PubMed ID: 12662439
    [TBL] [Abstract][Full Text] [Related]  

  • 56. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
    Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C;
    Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of tumor-infiltrating lymphocytes in the treatment of hepatic metastases arising from transgenic intraocular tumors in mice.
    Ma D; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1995 May; 36(6):1067-75. PubMed ID: 7730016
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
    Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
    J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study].
    Verdecchia GM; Ridolfi L; Ridolfi R; Riccobon A; Bertagni A; Vagliasindi A; Petrini M; Stefanelli M; Milandri C; Amadori D
    Tumori; 2003; 89(4 Suppl):298-300. PubMed ID: 12903626
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor.
    Figlin RA; Pierce WC; Kaboo R; Tso CL; Moldawer N; Gitlitz B; deKernion J; Belldegrun A
    J Urol; 1997 Sep; 158(3 Pt 1):740-5. PubMed ID: 9258071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.